WebAbstract P4-21-02: Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA) WebZurück zum Zitat Wuerstlein R, Harbeck N (2024) Neoadjuvant therapy for HER2-positive breast cancer. Rev Recent Clin Trials 12(2):81–92. doi: 10. 2174/ 1574887112666170 202465049 CrossRef Wuerstlein R, Harbeck N (2024) Neoadjuvant therapy for HER2-positive

走向治愈！妥妥双靶新辅助+辅助掀起HER2阳性早期乳腺癌系统治 …

In this randomized, double-blind, placebo-controlled, phase 3 trial,4,5 we enrolled patients who were at least 18 years of age with locally recurrent, unresectable, or metastatic HER2-positive breast cancer that was centrally confirmed. Eligible patients had a left ventricular ejection fraction (LVEF) of 50% or … See more The CLEOPATRA trial was performed in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of … See more We used the log-rank test to compare overall survival between the two treatment groups, with stratification according to status with respect to adjuvant or neoadjuvant … See more Study drugs were administered intravenously every 3 weeks. Pertuzumab (at a dose of 840 mg) or placebo was given on day 1 of cycle 1, followed by 420 mg on day 1 of each subsequent cycle; trastuzumab … See more Subgroup analyses were performed to ensure robustness of the treatment effect across prespecified categories. All analyses were performed with the use of SAS software, version 8.2 (SAS Institute). See more WebIntroduction. Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer have a poor prognosis. Despite proven efficacy with the standard of care, trastuzumab, most patients with HER2-positive metastatic breast cancer (MBC) will eventually progress, requiring further intervention to prolong life. Pertuzumab, a … the philanthropic pumpkin

Pertuzumab and trastuzumab in HER2-positive breast cancer BCTT

WebTRYPHAENA (NCT00976989) was a randomized, multicenter, open-label phase II study designed to evaluate the tolerability and activity associated with trastuzumab (Herceptin, … WebEnter the email address you signed up with and we'll email you a reset link. WebApr 9, 2024 · 发布时间：2024-4-09 the philanthropic society